1. Home
  2. FLUX vs MBRX Comparison

FLUX vs MBRX Comparison

Compare FLUX & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flux Power Holdings Inc.

FLUX

Flux Power Holdings Inc.

HOLD

Current Price

$0.65

Market Cap

14.3M

Sector

Miscellaneous

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.10

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLUX
MBRX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
16.1M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
FLUX
MBRX
Price
$0.65
$2.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
84.9K
516.1K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
N/A
N/A
Revenue
$9,317,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
126.25
N/A
52 Week Low
$0.66
$0.26
52 Week High
$7.55
$7.98

Technical Indicators

Market Signals
Indicator
FLUX
MBRX
Relative Strength Index (RSI) 31.72 39.36
Support Level N/A $1.90
Resistance Level $1.18 $2.64
Average True Range (ATR) 0.08 0.20
MACD -0.01 -0.06
Stochastic Oscillator 7.14 9.00

Price Performance

Historical Comparison
FLUX
MBRX

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: